Nephrology
Urolithiasis
9
Pipeline Programs↗
3
Active Trials↗
8
Companies Involved↗
Urolithiasis is an early-stage landscape with 9 programs across 8 companies. The most active players are Dawnrays Pharmaceutical (Holdings) Limited, AbbVie, Bayer. 6 therapies are approved.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 21
Phase 3
No programs
Analysis
Trial Status
10
clinical trials
Completed3 · 30%
Unknown status2 · 20%
Not yet recruiting2 · 20%
Terminated1 · 10%
Withdrawn1 · 10%
Recruiting1 · 10%
Clinical Trials
Trial Activity
10 trials
TCUPS- Tolvaptan Use in Cystinuria and Urolithiasis: A Pilot Study
Completed·—·N/A·NCT02538016·4 enrolled
Tamsulosin for Urolithiasis in the Emergency Dept
Completed·—·Phase 4·NCT00382265·512 enrolled
Effect of Vitamin D Replacement in Patients With Urolithiasis
Terminated·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT01349764·10 enrolled
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)